KSQ Therapeutics to Present First Data from its Proprietary CRISPRomics Discovery Engine
KSQ Therapeutics, a biotechnology company using CRISPR technology to enable the company's powerful discovery engine to achieve higher probabilities of success in drug development, today announced two upcoming presentations at leading scientific immuno-oncology congresses. The data demonstrate the capabilities of the company's proprietary CRISPRomics® discovery engine, which allows genome-scale, in vivo validated, unbiased drug discovery.
"There is a significant need for next-generation immuno-oncology therapies as the majority of cancer patients today experience an insufficient response to PD-1/PD-L1 therapies. The data we will be sharing demonstrate the potential of our CRISPRomics discovery platform to systematically identify and validate new cancer therapies for patients with PD-1 refractory solid tumors," said Frank Stegmeier, Ph.D., Chief Scientific Officer at KSQ Therapeutics. "KSQ was founded on the premise that CRISPR-enabled functional genomics can improve on current approaches to drug discovery and, taken together, these poster presentations describing the output of our genome-scale in vivo T-cell screens show that our platform can do this with a high degree of precision and quality, pointing the direction towards promising avenues of drug development."
Presentations include:
At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Comprehensive identification of novel therapeutic targets for treatment of PD-1 resistant solid tumors via a genome-scale CRISPR/Cas9 in vivo T-cell screen ? Poster # C101 ? Tuesday, October 29 - 3:30-4:00 p.m. - Level 2 Hall D
At the Society for Immunotherapy of Cancer's 34th Annual Meeting: An immune-CRISPRomics platform enabling genome-scale and pair-wise combination in vivo T-cell function screens enables comprehensive identification of novel therapeutic targets ? Poster # P550 ? Saturday, November 9 ? 12:35?2:05 p.m. and 7:00-8:35 p.m.
About KSQ Therapeutics
KSQ Therapeutics is using CRISPR technology to enable the company's powerful discovery engine to achieve higher probabilities of success in drug development. The company is advancing a pipeline of tumor- and immune-focused drug candidates for the treatment of cancer, across multiple drug modalities including targeted therapies, adoptive cell therapies and immuno-therapies. KSQ's proprietary CRISPRomics® discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies, and the company is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.ksqtx.com.
all® free clear, the #1 detergent brand recommended by dermatologists for sensitive skin, today announced it is partnering with Dr. Lindsey Zubritsky ? a board certified dermatologist and one of social media's most-followed...
Innovations in patient care developed at Florida Cancer Specialists & Research Institute, LLC (FCS) will be presented at the Oncology Nursing Society 49th Annual Congress in Washington, DC, the largest global gathering dedicated to oncology nursing....
FORUS Therapeutics Inc. ("FORUS") is deeply disappointed and disagrees with the recent decision by the Honourable Christian Dubé, Minister of Health and Social Services in Quebec to deny listing XPOVIO® (selinexor) in combination with VELCADE®...
The Inception Company, trusted provider of meeting solutions to the life sciences industry and HCPs (healthcare professionals) for over 20 years and known for its Pandotm platform, announces a pivotal role expansion for its in-house Executive...
n-Lorem, a nonprofit foundation, announced a new partnership with Hongene Biotech Corporation that supports n-Lorem's efforts to discover and provide personalized experimental antisense oligonucleotide (ASO) medicines to nano-rare disease patients (1...
Synaptogenix, Inc. ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on April 22,...